Sarepta Therapeutics
Develops Duchenne muscular dystrophy medicines and genetic therapies for rare diseases.
$21.05
After-hours close+0.21 (+0.98%)
At close$20.85(−3.45%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 104.68%Insiders 5.10%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 105.58M · Float 94.61M · 89.6% free float
Institutions13F, as of Jun 30, 2026
347 holders · 110.52M shares · 51 new positions · 153 increased · 116 reduced · 67 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 18.99M | 17.99% | +4.24M | Aug 7, 2026 |
| State Street Corp | 8.92M | 8.45% | +2.30M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.38M | 7.94% | +1.74M | Aug 13, 2026 |
| Two Sigma Investments, LP | 4.60M | 4.36% | +5.5K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.59M | 4.35% | +13.5K | Aug 13, 2026 |
| First Trust Advisors LP | 4.37M | 4.14% | +230.2K | Aug 11, 2026 |
| AQR Capital Management LLC | 4.33M | 4.10% | −2.11M | Aug 14, 2026 |
| Geode Capital Management, LLC | 2.77M | 2.63% | +783.0K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.60% | 13.23M | 13G | Jan 21, 2026 ↗ |
| State Street Corporation | 8.40% | 8.92M | 13G | Aug 7, 2026 ↗ |
| AQR Capital Management, LLC | 7.73% | 8.10M | 13G | Feb 13, 2026 ↗ |
| Vanguard Portfolio Management | 6.43% | 6.75M | 13G | Apr 29, 2026 ↗ |
| Vanguard Capital Management | 5.11% | 5.37M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Richard Barry | director | 2.98M | 2.83% | Jun 5, 2026 |
| Michael Severino | director, officer: Chief Executive Officer | 756.1K | 0.72% | Jul 29, 2026 |
| Douglas S. Ingram | director, officer: Chief Executive Officer | 490.3K | 0.46% | Dec 9, 2025 |
| Louise Rodino-Klapac | officer: President, R&D and Tech Ops | 225.3K | 0.21% | Mar 13, 2026 |
| M. Kathleen Behrens | director | 214.4K | 0.20% | Jun 5, 2026 |
| Ian Michael Estepan | officer: Chief Operating Officer | 202.0K | 0.19% | Mar 13, 2026 |
| Cristin Rothfuss | officer: EVP, General Counsel | 137.5K | 0.13% | Mar 13, 2026 |
| Ryan Ho-Yan Wong | officer: Chief Financial Officer | 135.1K | 0.13% | Mar 13, 2026 |
| Claude Nicaise | director | 48.4K | 0.05% | Jun 5, 2026 |
| Hans Lennart Rudolf Wigzell | director | 42.1K | 0.04% | Jun 5, 2026 |
4 ten-percent owners hold 4.31M shares by Form 4, outside the officers-and-directors figure above · 31 people have not refiled in the last 18 months (919.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 12, 2026 | Stephen Mayodirector | Sale | 7,239 | $17.02 | 1,765 |
| Dec 16, 2025 | Ian Michael Estepanofficer: Chief Operating Officer | Sale | 13,187 | $22.31 | 193,300 |
CongressHouse and Senate disclosures
Not reported.